Title
MLH1 intronic variants mapping to + 5 position of splice donor sites lead to deleterious effects on RNA splicing
Date Issued
01 October 2020
Access level
metadata only access
Resource Type
journal article
Author(s)
Piñero T.A.
Soukarieh O.
Rolain M.
Alvarez K.
López-Köstner F.
Torrezan G.T.
Carraro D.M.
De Oliveira Nascimento I.L.
Bomfim T.F.
Machado-Lopes T.M.B.
Freitas J.C.
Toralles M.B.
Sandes K.A.
Rossi B.M.
Junior S.A.
Meira J.
Møller P.
Vaccaro C.A.
Martins A.
Pavicic W.H.
Publisher(s)
Springer Science+Business Media B.V.
Abstract
Germline pathogenic variants in the DNA mismatch repair genes (MMR): MLH1, MSH2, MSH6, and PMS2, are causative of Lynch syndrome (LS). However, many of the variants mapping outside the invariant splice site positions (IVS ± 1, IVS ± 2) are classified as variants of unknown significance (VUS). Three such variants (MLH1 c.588+5G'C, c.588+5G'T and c.677+5G'A) were identified in 8 unrelated LS families from Argentina, Brazil and Chile. Herein, we collected clinical information on these families and performed segregation analysis and RNA splicing studies to assess the implication of these VUS in LS etiology. Pedigrees showed a clear pattern of variant co-segregation with colorectal cancer and/or other LS-associated malignancies. Tumors presented deficient expression of MLH1-PMS2 proteins in 7/7 of the LS families, and MSI-high status in 3/3 cases. Moreover, RNA analyses revealed that c.588+5G'C and c.588+5G'T induce skipping of exon 7 whereas c.677+5G'A causes skipping of exon 8. In sum, we report that the combined clinical findings in the families and the molecular studies provided the evidences needed to demonstrate that the three MLH1 variants are causative of LS and to classify c.588+5G'C and c.677+5G'A as class 5 (pathogenic), and c.588+5G'T as class 4 (likely-pathogenic). Our findings underline the importance of performing clinical and family analyses, as well as RNA splicing assays in order to determine the clinical significance of intronic variants, and contribute to the genetic counseling and clinical management of patients and their relatives.
Start page
323
End page
336
Volume
19
Issue
4
Language
English
OCDE Knowledge area
Oncología Biotecnología relacionada con la salud
Scopus EID
2-s2.0-85084212538
PubMed ID
Source
Familial Cancer
ISSN of the container
13899600
Sponsor(s)
This work was supported by the Agencia Nacional de Promoción Científica y Tecnológica [PICT-2017-3210 to C.V. and W.P.]; and the Instituto Nacional del Cáncer de Argentina [INC-Grant AFIV-2018/2020 to C.V. and W.P.]; and by Fundação de Amparo à Pesquisa do Estado de São Paulo [2014/50943-1 to DMC and GTT]. Moreover, this study was sponsored by the Groupement des Entreprise Françaises dans la Lutte contre le Cancer (Gefluc), and co-supported by the European Union and Région Normandie. Europe gets involved in Normandy with European Regional Development Fund (ERDF). This work was also supported by the Radium Hospital Foundation (Oslo, Norway), the Norwegian Cancer Society, contract 194751-2017 and Helse Sør-Øst (Norway). Acknowledgements
Sources of information: Directorio de Producción Científica Scopus